Another box ticked, and another step closer building this company into a major biotech player. Next catalyst recruitment commenced? I suspect as we move further into the P3 trial the market will realise just how undervalued this stock is, at less than $250m, for a company with such a late stage drug for such a major indication (noting that Vertex added $20b (that’s billion with a B) AUD to its market cap in the week following FDA approval for its pain drug)
Ann: Paradigm Secures Ethics Approval for Phase 3 Trial, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.010(3.33%) |
Mkt cap ! $112.9M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.5¢ | 29.0¢ | $123.6K | 421.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 36097 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 101917 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| PAR (ASX) Chart |